These types of mistakes are often described as “never events,” a term first coined in 2002 to refer to preventable medical ...

Pharma major Roche may have earned over a hundred times what risdiplam, a drug used to treat spinal muscular atrophy (SMA), ...

Scholar Rock Holding Corporation’s SRRK share price has dipped by 5.79%, which has investors questioning if this is right ...

Developments in genomics are enabling the rise of personalised medicine, with therapies tailored specifically for individuals ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

The global neurology clinical trials market is poised for substantial growth over the next decade, with projections forecasting an increase in market size from USD 5.7 billion in 2022 to a remarkable ...

Researchers studied 118 SMA type 2 patients and saw their RULM scores stayed higher than expected had their disease kept its ...

A number of the Dutch firm's products have received certification under Europe's In Vitro Diagnostic Regulation recently.